Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
CEFOTAN vs CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic